Skip to main content
Clinical Trials/ChiCTR-OOC-16008104
ChiCTR-OOC-16008104Not yet recruitingNot Applicable

绝经前乳腺癌患者化疗相关闭经预测指标的前瞻性研究

自筹1 site in 1 country50 target enrollmentStarted: April 1, 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
50
Locations
1
Primary Endpoint
窦卵泡素

Study Overview

Brief Summary

探讨(1)绝经前乳腺癌患者其化疗前血清窦卵泡素(antimullerian hormone,AMH)、卵泡刺激激素(follicle-stimulating hormone,FSH)、抑制素 B(inhibin B,inhB)及及窦卵泡计数(antral follicle counts,AFC)等,是否与患者发生化疗相关闭经(chemotherapy-related amenorrhea,CRA)相关;(2)确定绝经前乳腺癌患者化疗后卵巢功能恢复的预测指标及预测值。用以个体化指导生育功能保护、内分泌治疗方案制定等的临床决策。

Study Design

Study Type
观察性研究
Primary Purpose
队列研究

Eligibility Criteria

Ages
18 to 55 (—)
Sex
Female

Inclusion Criteria

  • (1)原发性可切除无远处转移的乳腺癌患者(2)入组前有规律月经(3)辅助化疗方案包含环磷酰胺(4)签署知情同意书

Exclusion Criteria

  • (1)既往或随访过程中患卵巢肿瘤,行双侧卵巢,子宫切除术,或行盆腔放疗
  • (4)使用促性腺激素释激素类似物

Arms & Interventions

绝经前乳腺癌患者

Outcomes

Primary Outcomes

窦卵泡素

卵泡刺素

抑制素 B

Secondary Outcomes

  • 窦卵泡计数
  • 雌二醇

Investigators

Sponsor
自筹

Study Sites (1)

Loading locations...

Similar Trials